title: A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
abstract: BACKGROUND
  To determine maximum tolerated dose (MTD), recommended dose, safety and pharmacokinetics of irofulven combined with cisplatin in advanced solid tumor patients.
  
  
  METHODS
  Cisplatin and irofulven were given sequentially i.v. over 30 min on day 1 and 15 every 4 weeks. Four dose levels (DL) were explored: irofulven (mg/kg)/cisplatin (mg/m2): DL1: 0.3/30; DL2: 0.4/30; DL3: 0.4/40; DL4: 0.5/40. Dose-limiting toxicity (DLT) included dosing omission and delay > 1 week. MTD was the DL with DLT in 2/2 or > or = 2/6 patients during cycle 1-2.
  
  
  RESULTS
  Between March 2002 and April 2003, 33 patients were treated. DLT occurred in 1/6 patients in DL1 (hypomagnesemia, hypocalcemia); 1/6 in DL2 (thrombocytopenia); 2 heavily pretreated patients out of 6 patients in DL3 (neutropenic infection, thrombocytopenia, stomatitis); 2/3 in DL4 (asthenia, blurred vision). Three DLT occurred in 12 additional patients treated at DL2. No toxic deaths occurred; grade 4 toxicity and grade 3 non-hematological toxicity were infrequent. Six patients reported grade 1-2 visual events. Antitumor activity was observed over a broad spectrum of tumor types in all DLs: 1 partial response in bulky sarcoma (DL1); 1 clinical response in endometrial carcinoma (DL1); 2 partial responses not confirmed due to discontinuation (ovarian DL2, renal DL4); 8 stabilizations > 3 months; PSA response: 3/9 prostate cancer patients. Irofulven showed rapid elimination and high interpatient variability. Platinum and irofulven pharmacokinetics did not suggest drug-drug interactions.
  
  
  CONCLUSIONS
  Irofulven with cisplatin was adequately tolerated and substantial evidence of antitumor activity was observed. The recommended dose is irofulven 0.4 mg/kg and cisplatin 30 mg/m2.
authors: Hôpital Saint-Louis, Paris, France.
authors: Werner
authors: W
authors: Hilgers
authors: Sandrine
authors: S
authors: Faivre
authors: Stéphanie
authors: S
authors: Chieze
authors: Jérôme
authors: J
authors: Alexandre
authors: François
authors: F
authors: Lokiec
authors: François
authors: F
authors: Goldwasser
authors: Eric
authors: E
authors: Raymond
authors: Carmen
authors: C
authors: Kahatt
authors: Abdelkrim
authors: A
authors: Taamma
authors: Garry
authors: G
authors: Weems
authors: John R
authors: JR
authors: MacDonald
authors: Jean-Louis
authors: JL
authors: Misset
authors: Esteban
authors: E
authors: Cvitkovic